Quote:

---

All that have been in bio any length of time should know you can almost guarantee delays and missed deadlines.

---

While your approach is healthy (i.e. “live your life”) I would argue investors in Cytodyn have gone through way more trials and tribulations than your average biotech shareholder.

Take the 13D and Amarex, just for starters.

And those four-leaf clovers? Why wouldn’t you have high expectations for a platform drug with no SAEs? Name another drug comparable.

I think the optimism of most shareholders has been founded, whereas the level of obstacles (and missteps) and disappointment unprecedented.